APS ROS'G PCT/PTO 20 APR 2006
ATTORNEY DOCKET NO. 21101.0040U2
PATENT

APR 2 0 2006

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Kishore, et al.) Art Unit: 1651
Application No. 10/552,568) Examiner: Unassigned
Filing Date: October 11, 2005) Confirmation No. 2536
For: "COMPOSITIONS AND METHODS RELATED TO PRODUCTION OF ERYTHROPOIETIN")

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C. Customer Number 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. §1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.

This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.

338663

ATTORNEY DOCKET NO. 21101.0040U2 Application No. 10/552,568

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

David E. Huizenga, J.D., Ph.D.

Registration No. 49,026

NEEDLE & ROSENBERG, P.C. Customer Number 23859 (678) 420-9300 (678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.

vid E. Huizenga, J.D., Ph.D.

Date

-							plete if Kn		
NF	ORMA	ATION DISCL	OSURI	E		ation Number	10/552	·	
STATEMENT LIST APR 2 0 2006 (Use as many sheets as necessary)			Filing Date First Named Inventor		October 11, 2005 Kishore, et al.				
									Group
				5				Exam	iner Name
)	*/		U.S.	PATENT	DOC	IMENTS			
Initials	Cite No.	Document No.		Date		Name	Class	Subclass	Filing Date (if appropriate
muais	A1	4,526,888	July 2,	1985		Williams, et al.			
	A2	4,667,016	May 19	, 1987		Lai, et al.			
	A3	4,703,008	October	r 27, 1987		Lin			
	A4	4,935,350	June 19	9, 1990		Patel, et al.			
	A5	4,987,121	January	, 22, 1991		Baertschi, et al.			
	A6	5,032,507	July 16,	1991		Yu, et al.	1		
-	A7	5,104,653	April 14	, 1002		Michalevicz			
	A8	5,106,760	April 21	, 1992		Egrie			
	A9	5,354,934	Ocotbe	r 11, 1994	•	Pitt, <i>et al.</i>			
	A10	5,476,653	Decemb	ber 19, 199	95	Pitt, <i>et al.</i>			
	A11	5,482,924	January	/ 9, 1996		Royet, et al.			
	A12	5,547,933	August	20, 1996		Lin			
-	A13	5,621,080	April 15	, 1997		Lin			
	A14	5,618,698	April 8,	1997		Lin			
	A15	5,661,125	August	26, 1997		Strickland			· · · · · · · · · · · · · · · · · · ·
	A16	5,756,349	May 26	, 1998	1	Lin			
	A17	5,830,705	Novemb	ber 3, 1998	8	Souza			
··· -	A18	5,885,574	March 2	23, 1999		Elliott			
	A19	5,597,562	January	, 28, 1997		Nomura, et al.			
-	A20	5,955,422	Septem	ber 21, 19	99	Lin			
	A21	6,221,397 B1	April 24	, 2001	,	Russell-Jones, et al.			
	A22	6,319,499	Novemb	ber 20, 200	01	Elliott			
	A23	6,784,154 B2	August	31, 2004		Westenfelder			
						CUMENTS			
Examiner's nitials	Cite No.	Foreign Patent Do Country Code-N Kind Code	umAer-		ate	Name	•		nslation es/No
	A24	WO 01/66149 A	2	09/13/01		Valentis, Inc.			
	1			N-PATENT				* * * * * * * * * * * * * * * * * * * *	
xaminer's nitials	Cite No.					sher, Relevant Page			
	A25	Abbate, M., et al Res 22:37-46, 1		nuria as a r	mediato	or of tubulointerstit	ial injury,	' Kidney Blo	od Press
	A26	Anagnostou, A., sham-operated				t erythropoiesis in 76	partially	nephrectom	ized and

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, wheth	ner or not citation is in conformance with MPEP 609; draw line through citation
if not in conformance and not considéred. Include co	nov of this form with next communication to applicant.



NEODIATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Com	plete if Known	
Application Number	10/552,568	
Filing Date	October 11, 2005	
First Named Inventor	Kishore, et al.	
Group Art Unit	1651	
Examiner Name	Unassigned	

		Examine Name Onassigned					
		NON-PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, PuAlisher, Relevant Pages, Date and Place of PuAlication)					
	A27	Bachmann, S., et al., "Co-localization of erythropoietin messenger RNA and ecto-5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that fibroblasts produce erythropoietin," J. Histochem Chytochem 41:335-341, 1993					
	A28	Bellizzi, V., et al., "The impact of early normalization of haematocrit by erythropoietin on renal damage in the remnant kidney model, Nephrol Dial. Transplant 13:2210-2215, 1998					
	A29	Browne, et al., "Erythropoietin: Gene cloning, protein structure, and biological properties," Cold Spring Harbor Symposia on Quantitative Biology, L1:693-702, 1986					
	A30	Burton, C., et al., "The role of proteinuria in the progression of chronic renal failure," Am. J. Kidney Dis. 27:765-775, 1996					
	A31	Carlini, R., et al., "Recombinant human erythropoietin stimulates angiogenesis in vitro," Kidney, Int. 47:740-745, 1995					
	A32	Dendorfer, U., "Molecular biology of cytokines, Art. Organs," 20:437-444, 1996					
	A33	Donnelly, S., "Why is erythropoietin made in the kidney? The kidney functions as a critmeter," Am J. Kidney Dis. 38:415-425, 2001					
	A34	Eddy, A.A., "Interstitial nephritis induced by protein overland proteinuria," Am. J. Pathol. 135:719-733, 1989					
	A35	Eddy, A.A., "Molecular basis of renal fibrosis," Pediatr. Nephrol. 15:290-301, 2000					
	A36	Eddy, A.A., "Role of cellular infiltrates in response to proteinuria," Am. J. Kidney Dis., 37:S25-S29, 2001					
	A37	Ferrara, N., "Molecuar and biological properties of vascular endothelial growth factor, J. Mole. Med. 77:527-543, 1999					
	A38	Gandi, R., et al., "Immunolocalization of ecto-5'-nucleotidase in the kidney by a monoclonal antibody," Histochemistry 95:165-174, 1990					
	A39	Ghielli, M., et al., "Inflammatory cells in renal pathology," Néphrologie 19:59-67, 1998					
	A40	Gleadle, J.M. et al., "Induction of hypoxia-inducible factor-1 erythropoietin, vascular endothelial growth factor and glucose transporter-1 by hypoxia: evidence against a regulatory role for Src kinase," Blood 89:503-509, 1997					
	A41	Ivan, M., et al., "HIF alpha targeted for VHL-mediated destruction by praline hydroxylation: implications for O ₂ sensing," Science 292:464-468, 2001					
	A42	Jaakkola, P., et al., "Targeting of HIF alpha to the von Hippel-Lindau urbiquitylation complex by O ₂ regulated prolyl hydroxylation," Science 292:468-472, 2001					
	A43	Jelkmann, W., "Erythropoietin: structure, control of production, and function," Physio. Rev. 72:449-489, 1992					
	A44	Johnson, D.W., "Human renal fibroblasts modulate proximal tubule cell growth and transport via the IGF-1 axis," Kidney Int. 52:1486-1496, 1997					
	A45	Kaissling, B., "Morphology of interstitial cells in the healthy kidney, Anat. Embryol. 193:303-318, 1996					

Examiner Signature:	Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APR 2 0 2006 W

NFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Com	plete if Known	
Application Number	10/552,568	
Filing Date	October 11, 2005	
First Named Inventor	Kishore, et al.	
Group Art Unit	1651	
Examiner Name	Unassigned	

		NON-PATENT DOCUMENTS			
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, PuAlisher, Relevant Pages, Date and Place of PuAlication)			
	A46	Keane, W.F.,"Proteinuria: its clinical importance and role in progressive renal disease, AM. J. Kidney Dis. 35:S97-S105, 2000			
	A47	Kendall, R.G., "Erythropoietin," Clin. Lab. Hematol. 23:71-80, 2001			
	A48	Kishore, B.K., "Mechanism of the thesaurismosis and altered lysosomal dynamics induced by poly-D-glutamic acid in kidney proximal tubular cells," Lab. Invest. 74:1025-1037, 1996			
	A49	Kishore, B.K., et al., "Expression of renal aquaporins 1, 2, and 3 in a rat model of cisplatin-induced polyuria," Kidney Int. 58:701-711, 2000			
	A50	Kishore, B.K., et al., "Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis II. Comparative in vitro and in vivo studies with poly-Laspartic, poly-L-glutamic and poly-D-glutamic acids," J. Pharmacol. Exp. Ther. 255:875-885, 1990			
	A51	Kishore, B.K., et al., "Poly-D-glutamic acid induces an acute lysosomal thesaurismosis of proximal tubules and a marked proliferation of interstitium in rat kidney," Lab. Invest. 74:1013-1023, 1996			
	A52	Koury, S., et al., "Localization of erythropoietin synthesizing cells in murine kidneys by in situ hybridization," Blood 71:524-527, 1988			
	A53	Koury, S., et al., "Quantitation of erythropoietin-producing cells in kidneys of mice by in situ hybridization. Correlation with hamtocrit, renal erythropoietin mRNA and serum erythropoietin concentration," Blood 74:645-651, 1989			
	A54	Krantz, S., "Erythropoietin," Blood 77:419-434, 1991			
	A55	Lacombe, C., et al., "The molecular biology of erythropoietin, Nephrol. Dial. Transplant 14:22-28, 1999			
	A56	Lando, D.F., et al., "Aspargine hydroxylation of HIF alpha transactivation domain: a hypoxic switch," Science 295:858-861, 2002			
	A57	Le Hir, et al., "Distribution of 5'-nuclleotides in the renal interstitium of the rat," Cell Tissue Res. 258:177-182, 1989			
	A58	Maxwell, et al., "The interstitial response to renal injury: fibroblast-like cells show phenotypic changes and have reduced potential for erythropoietin gene expression, Kidney Int., 52:715-724, 1997			
	A59 Maxwell, et al., "Identification of the renal erythropoietin producing cells using transgenic mice," Kidney Int. 44:1149-1162, 1993 A60 Priyadarshi, A., et al., "Effects of reduction of renal mass on renal oxygen tension and erythropoietin production in the rate," Kidney Int. 61:542-546, 2002 A61 Ribatti, D., "Human erythropoietin induces a pro-angiogenic phenotype in cultered endother cells and stimulates neovascularization in vivo," Blood 93:2627-2636, 1999 A62 Schena, F.P, "Cytokine network and resident renal cells in glomerular diseases. Nephol. Expression of the renal renal and renal erythropoietin production in anal rats," Brit. J. Hemat. 81:153-159, 1992				

Examiner Signature:) :
---------------------	----------------

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Corr	plete if Known
Application Number	10/552,568
Filing Date	October 11, 2005
First Named Inventor	Kishore, et al.
Group Art Unit	1651
Examiner Name	Unassigned

	•	Examiner Name Unassigned
···		NON-PATENT DOCUMENTS
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, PuAlisher, Relevant Pages, Date and Place of PuAlication)
	A64	Shih, S.C., et al., "Hypoxia-mediated regulation of gene expression in mammalian cells," Int. J. Exp. Pathol. 79:347-357, 1998
	A65	Todd, et al. Poly-L-Aspartic Acid Protects Cultured Human Proximal Tubule Cells Against Aminoglycoside-Induced Electrophysiological Alterations, Toxicology Lett. Vol. 90, Nos. 2 and 3:217-221, see Figures 1 and 2, 1997
	A66	von Kooten, C., et al., "Role of tubular cells in progressive renal disease," Kidney Blood Press. Res. 22:53-61, 1999
	A67	Westenfelder, C., "Unexpected renal actions of erythropoietin," Exp. Nephrol. 10:294-298, 2002
	A68	Westenfelder, C., et al., "Erythropoietin stimulates proliferation of human renal carcinoma cells," Kidney Int. 58:647-657, 2000
	A69	Westenfelder, C., et al., "Erythropoietin treatment ameliorates ischemic acute renal failure in rats by its anti-apoptotic, motogenic and mitogenic actions, J. Am. Soc. Nephrol 12:793A, 2001
)	A70	Westenfelder, C., et al., "Human, rat and mouse kidney cells express functional erythropoietin receptors," Kidney Int. 55:808-820, 1999
	A71	Westenfelder, C., et al., "Dual roles of NFkB in ischemic acture renal fauilure in rats: (1) mediates maladaptive suppression of erythropoietin (EPO) gene, (2) mediate EPO's antiapoptotic effects in proximal tubular cells. Abstract #T323 accepted for presentation at the World Congress of Nephrology, Berlin, June 8-12, 2003
	A72	Wolf, G., et al., "Molecular mechanisms of tubulointerstitial hypertrophy and hyperplasia, Kidney Int. 39:401-420, 1991
	A73	Youssoufian, H., et al., "Structure, function, and activation of the erythropoietin receptor," Blood 81:2223-2236, 1993
	A74	Zoja, C., et al.," Protein overload activates proximal tubular cells to release vasoactiove and inflammatory mediators," Exp. Nephrol. 7:420-428, 1999

Examiner	Signature:
----------	------------

Date Considered:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.